9,326,945 (945) in litigation to further delay generic competitors
With advancements in medical research, new therapies have emerged to address the challenges faced by patients
Our peptides are intended for research purposes only and are not for human consumption

Semaglutide is officially approved for specific groups of people who meet certain criteria: For weight loss (Wegovy) Wegovy is approved for use in: Adults with a BMI 30 (obesity), or Adults with a BMI 27 (overweight) with at least one weight-related condition: Type 2 diabetes High blood pressure High cholesterol Sleep apnea Cardiovascular disease For Type 2 diabetes (Ozempic/Rybelsus) Ozempic and Rybelsus are approved for use in: Adults with type 2 diabetes who need better blood sugar control Those at high risk for cardiovascular events Patients who haven't achieved blood sugar goals with other medications Wegovy for heart health Wegovy is approved for use in: Adults with established cardiovascular disease who are overweight or obese People with type 2 diabetes with heart disease risk factors You might be a candidate for semaglutide if you: Have struggled with traditional diet and exercise alone Need to lose weight for health reasons Can commit to weekly injections (or daily pills for Rybelsus) Are willing to make lifestyle changes alongside medicationdiet and exercise are key Have realistic expectations about gradual weight loss Can afford long-term treatment (insurance coverage varies) Please consult your healthcare provider about whether semaglutide is right for you

Also, comparatively high insurance coverage in the US albeit with requirements concerning prior authorization, offers coverage to 70-80% of patients with conditions that allow GLP-1 therapy with out-of-pocket costs that are manageable, unlike in less price-sensitive international markets
These medications mimic the hormone GLP-1, which helps regulate appetite, increase feelings of fullness, and control blood sugar levels